IDEXX Laboratories Set to Announce Q4 Earnings on February 2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: seekingalpha
- Earnings Announcement: IDEXX Laboratories is set to release its Q4 earnings on February 2 before market open, with consensus EPS estimates at $2.94 and revenue expected to reach $1.07 billion, reflecting a 12.2% year-over-year growth that will solidify its leadership in the diagnostics market.
- Historical Performance: Over the past two years, IDEXX has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, demonstrating financial stability and market confidence, which is likely to attract more investor interest.
- Estimate Revision Trends: In the last three months, EPS estimates have seen four upward and four downward revisions, while revenue estimates have experienced ten upward revisions with none downward, indicating analysts' optimistic outlook on IDEXX's future performance, potentially driving stock price increases.
- Growth Outlook: IDEXX forecasts a revenue growth rate of 9.6% to 10.3% for 2025, driven by robust expansion in its CAG diagnostics business, which will further enhance investor confidence and may elevate its market valuation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IDXX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IDXX
Wall Street analysts forecast IDXX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDXX is 792.78 USD with a low forecast of 750.00 USD and a high forecast of 850.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 676.710
Low
750.00
Averages
792.78
High
850.00
Current: 676.710
Low
750.00
Averages
792.78
High
850.00
About IDXX
IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IDEXX Laboratories Set to Announce Q4 Earnings on February 2
- Earnings Announcement: IDEXX Laboratories is set to release its Q4 earnings on February 2 before market open, with consensus EPS estimates at $2.94 and revenue expected to reach $1.07 billion, reflecting a 12.2% year-over-year growth that will solidify its leadership in the diagnostics market.
- Historical Performance: Over the past two years, IDEXX has beaten EPS estimates 100% of the time and revenue estimates 63% of the time, demonstrating financial stability and market confidence, which is likely to attract more investor interest.
- Estimate Revision Trends: In the last three months, EPS estimates have seen four upward and four downward revisions, while revenue estimates have experienced ten upward revisions with none downward, indicating analysts' optimistic outlook on IDEXX's future performance, potentially driving stock price increases.
- Growth Outlook: IDEXX forecasts a revenue growth rate of 9.6% to 10.3% for 2025, driven by robust expansion in its CAG diagnostics business, which will further enhance investor confidence and may elevate its market valuation.
Continue Reading
GE Aerospace Stock Up 23.9% Driven by Strong Demand for Commercial Engines
- Strong Market Performance: GE Aerospace's stock has risen 23.9% over the past six months, significantly outperforming the Aerospace-Defense industry’s 15% growth, indicating robust demand in commercial engines and propulsion technologies.
- Dividend Increase: In February 2025, GE Aerospace raised its dividend by 28.6% to $0.36 per share, reflecting a commitment to shareholder returns and signaling improved financial health.
- Cost Challenges: Despite facing high costs and restructuring pressures that may impact margins, the company's diversified international operations help mitigate some of these risks.
- Foreign Exchange Risks: GE Aerospace's international presence exposes it to foreign exchange fluctuations, which could affect overall profitability, especially amid increasing global economic uncertainties.
Continue Reading